Ryan K. Stansfield

1.2k citations

17 papers · 1.0k · h-index 12

Impact in

Molecular Biology
- Epigenetics and DNA Methylation
- Inflammasome and immune disorders
- Protein Kinase Regulation and GTPase Signaling
- DNA and Nucleic Acid Chemistry
Organic Chemistry top 10%
- Synthesis and biological activity

Papers in

Genetics 2
- Chronic Lymphocytic Leukemia Research 2
Molecular Biology 5
- Inflammasome and immune disorders 4
- Protein Degradation and Inhibitors 1

Co-authors: James M. Veal (8 shared papers)Jeffrey A. Stafford (7 shared papers)Lihong Shi (5 shared papers)Chon Lai (4 shared papers)David J. Hosfield (4 shared papers)Shawn M. O’Connell (4 shared papers)Denis Drygin (3 shared papers)Jiangchun Xu (4 shared papers)
Journals: Bioorganic & Medicinal Chemistry Letters (4 papers)Journal of Medicinal Chemistry (3 papers)ACS Medicinal Chemistry Letters (3 papers)Blood (2 papers)Molecular and Cellular Biochemistry (1 paper)
Partner nations: United States Portugal Italy

In The Last Decade

Ryan K. Stansfield

17 papers receiving 1.0k citations

Peers

Countries citing papers authored by Ryan K. Stansfield

Since Specialization

Citations

This map shows the geographic impact of Ryan K. Stansfield's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ryan K. Stansfield with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ryan K. Stansfield more than expected).

Fields of papers citing papers by Ryan K. Stansfield

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ryan K. Stansfield. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ryan K. Stansfield. The network helps show where Ryan K. Stansfield may publish in the future.

Co-authors

The 25 scholars most cited alongside Ryan K. Stansfield, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Ryan K. Stansfield Line = papers co-authored together Ryan K. Stansfield links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work
1	Discovery and SAR of 5-(3-Chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic Acid (CX-4945), the First Clinical Stage Inhibitor of Protein Kinase CK2 for the Treatment of Cancer Journal of Medicinal Chemistry ·Fabrice Pierre, Peter C. Chua, Sean O’Brien, Adam Siddiqui-Jain, Pauline Bourbon, Mustapha Haddach, Jerome Michaux, Johnny Y. Nagasawa	2010	264
2	Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer Molecular and Cellular Biochemistry ·Fabrice Pierre, Peter C. Chua, Sean O’Brien, Adam Siddiqui-Jain, Pauline Bourbon, Mustapha Haddach, Jerome Michaux, Johnny Y. Nagasawa	2011	135
3	Discovery of CX-5461, the First Direct and Selective Inhibitor of RNA Polymerase I, for Cancer Therapeutics ACS Medicinal Chemistry Letters ·Mustapha Haddach, Michael K. Schwaebe, Jerome Michaux, Johnny Y. Nagasawa, Sean O’Brien, Jeffrey P. Whitten, Fabrice Pierre, Pauline Kerdoncuff	2012	126
4	Discovery of CC-90011: A Potent and Selective Reversible Inhibitor of Lysine Specific Demethylase 1 (LSD1) Journal of Medicinal Chemistry ·Toufike Kanouni, Christophe Severin, Robert W. Cho, Natalie Yuen, Jiangchun Xu, Lihong Shi, Chon Lai, Joselyn R. Del Rosario	2020	103
5	Discovery of CX-6258. A Potent, Selective, and Orally Efficacious pan-Pim Kinases Inhibitor ACS Medicinal Chemistry Letters ·Mustapha Haddach, Jerome Michaux, Michael K. Schwaebe, Fabrice Pierre, Sean O’Brien, Cosmin Borsan, Joe A. Tran, Nicholas Raffaele	2011	78
6	Activity of the clinical-stage CK2-specific inhibitor CX-4945 against chronic lymphocytic leukemia Leukemia ·Leila R. Martins, Paulo Lúcio, Alice Melão, Inês Antunes, Bruno A. Cardoso, Ryan K. Stansfield, Maria Teresa Sabrina Bertilaccio, Paolo Ghia	2013	68
7	Design of KDM4 Inhibitors with Antiproliferative Effects in Cancer Models ACS Medicinal Chemistry Letters ·Young K. Chen, Tiziana Bonaldi, Alessandro Cuomo, Joselyn R. Del Rosario, David J. Hosfield, Toufike Kanouni, Shih-Chu Kao, Chon Lai	2017	67
8	Overcoming Preclinical Safety Obstacles to Discover (S)-N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-6-(methylamino)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide (GDC-2394): A Potent and Selective NLRP3 Inhibitor Journal of Medicinal Chemistry ·Christopher McBride, Lynnie Trzoss, Davide Povero, Miloš Lazić, Géza Ambrus-Aikelin, Angelina M. Santini, Rama F. Pranadinata, Gretchen Bain	2022	65
9	Structure-based design and discovery of potent and selective KDM5 inhibitors Bioorganic & Medicinal Chemistry Letters ·Zhe Nie, Lihong Shi, Chon Lai, Shawn M. O’Connell, Jiangchun Xu, Ryan K. Stansfield, David J. Hosfield, James M. Veal	2018	36
10	Novel potent pyrimido[4,5-c]quinoline inhibitors of protein kinase CK2: SAR and preliminary assessment of their analgesic and anti-viral properties Bioorganic & Medicinal Chemistry Letters ·Fabrice Pierre, Sean O’Brien, Mustapha Haddach, Pauline Bourbon, Michael K. Schwaebe, Eric Stefan, Levan Darjania, Ryan K. Stansfield	2011	31
11	JT002, a small molecule inhibitor of the NLRP3 inflammasome for the treatment of autoinflammatory disorders Scientific Reports ·Géza Ambrus-Aikelin, Katsuyuki Takeda, Anthony Joetham, Miloš Lazić, Davide Povero, Angelina M. Santini, Rama F. Pranadinata, Casey D. Johnson	2023	24
12	Structure-based design and discovery of potent and selective lysine-specific demethylase 1 (LSD1) inhibitors Bioorganic & Medicinal Chemistry Letters ·Zhe Nie, Lihong Shi, Chon Lai, Christophe Severin, Jiangchun Xu, Joselyn R. Del Rosario, Ryan K. Stansfield, Robert W. Cho	2018	12
13	Design, synthesis and biological evaluation of novel 4-phenylisoquinolinone BET bromodomain inhibitors Bioorganic & Medicinal Chemistry Letters ·Yiqin Wu, Amogh Boloor, Jennifer Matuszkiewicz, Shawn M. O’Connell, Lihong Shi, Ryan K. Stansfield, Joselyn R. Del Rosario, James M. Veal	2018	9
14	Pharmacology of a Potent and Novel Inhibitor of the NOD-Like Receptor Pyrin Domain-Containing Protein 3 (NLRP3) Inflammasome that Attenuates Development of Nonalcoholic Steatohepatitis and Liver Fibrosis Journal of Pharmacology and Experimental Therapeutics ·Davide Povero, Miloš Lazić, Christopher McBride, Géza Ambrus-Aikelin, Ryan K. Stansfield, Casey D. Johnson, Angelina M. Santini, Rama F. Pranadinata	2023	9
15	In Vitro and in Vivo Targeting of Chronic Lymphocytic Leukemia Using CX-4945, a Clinical-Stage CK2-Specific Inhibitor. Blood ·Leila R. Martins, Paulo Lúcio, Alice Melão, Bruno A. Cardoso, Ryan K. Stansfield, Denis Drygin, María Gomes da Silva, João Taborda Barata	2012	3
16	Discovery of Selective Small Molecule Pan-Pim Kinase Inhibitors with Potent Oral Efficacy in Murine Xenograft Models. Blood ·Sean O’Brien, Mustapha Haddach, Cosmin Borsan, Jerome Michaux, Pauline Kerdoncuff, M.T.K. Schwaebe, Fabrice Pierre, Eric Stefan	2009	1
17	Discovery of Inhibitors of NLRP3 inflammasome assembly for the treatment of NASH and liver fibrosis Journal of Hepatology ·James M. Veal, Chris McBride, Miloš Lazić, Davide Povero, György Ambrus, Angelina M. Santini, Ryan K. Stansfield, Lynnie Trzoss	2018	1

About Ryan K. Stansfield

Ryan K. Stansfield is a scholar working on Genetics, Molecular Biology, Nuclear Energy and Engineering, Waste Management and Disposal and Infectious Diseases, having authored 17 papers that have together received 1.0k indexed citations. Recurring topics across this work include Inflammasome and immune disorders (4 papers), Chronic Lymphocytic Leukemia Research (2 papers) and Protein Degradation and Inhibitors (1 paper). The work is most often cited by research in Molecular Biology (271 citations), Organic Chemistry (125 citations), Computational Theory and Mathematics (58 citations), Genetics (22 citations) and Oncology (37 citations). Ryan K. Stansfield has collaborated with scholars based in United States, Portugal and Italy. Frequent co-authors include James M. Veal, Jeffrey A. Stafford, Lihong Shi, Chon Lai, David J. Hosfield, Shawn M. O’Connell, Denis Drygin, Jiangchun Xu, Toufike Kanouni and Young K. Chen. Their work appears in journals such as Bioorganic & Medicinal Chemistry Letters, Journal of Medicinal Chemistry, ACS Medicinal Chemistry Letters, Blood and Molecular and Cellular Biochemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Ryan K. Stansfield

Impact in

Papers in i

In The Last Decade

Ryan K. Stansfield

Peers

Countries citing papers authored by Ryan K. Stansfield

Fields of papers citing papers by Ryan K. Stansfield

All Works

About Ryan K. Stansfield

Explore authors with similar magnitude of impact

Papers in